<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37067648</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Association of interleukin 33 gene polymorphisms with susceptibility and regulation of inflammatory mediators in Systemic lupus erythematosus patients.</ArticleTitle><Pagination><StartPage>2187</StartPage><EndPage>2197</EndPage><MedlinePgn>2187-2197</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06575-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies have indicated the involvement of interleukin (IL)-33 in the pathogenesis of Systemic lupus erythematosus (SLE). This research intended to evaluate the association of IL33 gene rs1929992 and rs7044343 Single nucleotide polymorphisms (SNPs) with risk of SLE. In addition, the association between these SNPs and inflammatory cytokines was determined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, 200 SLE cases and 200 healthy subjects were recruited. Using allelic discrimination Real-time PCR, IL33 gene rs1929992 and rs7044343 SNPs were genotyped. The mRNA expression levels of IL-1&#x3b2;, IL-6, IL-33, TNF-&#x3b1; were determined in the peripheral blood mononuclear cells (PBMCs). The serum levels of cytokines were also measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The G allele (OR&#x2009;=&#x2009;1.57, CI: 1.18-2.08, P&#x2009;=&#x2009;0.0017), GG genotype (OR&#x2009;=&#x2009;2.52, CI: 1.33-4.77, P&#x2009;=&#x2009;0.0043), and GA genotype (OR&#x2009;=&#x2009;2.12, CI: 1.34-3.34, P&#x2009;=&#x2009;0.0011) of rs1929992 SNP was significantly associated with an increased SLE risk. The C allele (OR&#x2009;=&#x2009;1.44, CI: 1.08-1.90; P&#x2009;=&#x2009;0.0105), CC genotype (OR&#x2009;=&#x2009;2.07, CI: 1.15-3.71; P&#x2009;=&#x2009;0.0146), and CT genotype (OR&#x2009;=&#x2009;1.61, CI: 1.02-2.53, P&#x2009;=&#x2009;0.0395) of rs7044343 was significantly associated with increased SLE risk. The PBMC mRNA expression and serum levels of IL-1&#x3b2;, IL-6, IL-33, TNF-&#x3b1; were significantly increased in the SLE patients compared to controls. However, there was no significant difference in the mRNA expression and serum levels of IL-1&#x3b2;, IL-6, IL-33, and TNF-&#x3b1; among the SLE patients with three genotypes for both rs1929992 and rs7044343 polymorphisms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IL33 gene rs1929992 and rs7044343 SNPs are involved in SLE pathogenesis but they might not influence on the inflammatory pathway.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagheri-Hosseinabadi</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzaei</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliakbari</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbasifard</LastName><ForeName>Mitra</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8149-8549</Identifier><AffiliationInfo><Affiliation>Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. dr.abbasifard.m@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. dr.abbasifard.m@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IR.RUMS.REC.1400.172</GrantID><Agency>Rafsanjan University of Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067596">Interleukin-33</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067596" MajorTopicYN="Y">Interleukin-33</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IL-33</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Single nucleotide polymorphism</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37067648</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06575-y</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06575-y</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Trentin F, Zucchi D, Signorini V et al (2021) One year in review 2021: systemic lupus erythematosus. Clin Exp Rheumatol 39:231&#x2013;41. https://doi.org/10.55563/clinexprheumatol/7gzsxp</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/7gzsxp</ArticleId><ArticleId IdType="pubmed">33843578</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Reis PC et al (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12:716&#x2013;730. https://doi.org/10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathollahi A, Gabalou N, Aslani S (2018) Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder. Lupus 27:1053&#x2013;1064. https://doi.org/10.1177/0961203318768889</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318768889</ArticleId><ArticleId IdType="pubmed">29631514</ArticleId></ArticleIdList></Reference><Reference><Citation>Javinani A, Ashraf-Ganjouei A, Aslani S et al (2019) Exploring the etiopathogenesis of systemic lupus erythematosus: a genetic perspective. Immunogenetics 71:283&#x2013;297. https://doi.org/10.1007/s00251-019-01103-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-019-01103-2</ArticleId><ArticleId IdType="pubmed">30671674</ArticleId></ArticleIdList></Reference><Reference><Citation>Foma AM, Aslani S, Karami J et al (2017) Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous. Inflamm Res 66:1057&#x2013;1073. https://doi.org/10.1007/s00011-017-1082-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-017-1082-y</ArticleId><ArticleId IdType="pubmed">28741130</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmaninejad A, Mahmoudi M, Aslani S et al (2017) Association of STAT4 gene single nucleotide polymorphisms with Iranian juvenile-onset systemic lupus erythematosus patients. Turkish J Pediatr 59:144&#x2013;9. https://doi.org/10.24953/turkjped.2017.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.24953/turkjped.2017.02.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimiyan H, Rezaei R, Mostafaei S et al (2018) Association study between STAT4 polymorphisms and susceptibility to systemic lupus erythematosus disease: A systematic review and meta-analysis. Meta Gene 16:241&#x2013;247. https://doi.org/10.1016/j.mgene.2018.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mgene.2018.03.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi M, Aslani S, Hamzeh E et al (2017) Association study of MECP2 gene single nucleotide polymorphisms in juvenile-onset systemic lupus erythematosus patients from Iran. Fetal Pediatr Pathol 36:423&#x2013;431. https://doi.org/10.1080/15513815.2017.1367871</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15513815.2017.1367871</ArticleId><ArticleId IdType="pubmed">29199882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimiyan H, Mostafaei S, Aslani S et al (2022) Association between complement gene polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Med.&#xa0;22(3):427&#x2013;438.&#xa0; https://doi.org/10.1007/s10238-021-00758-0</Citation></Reference><Reference><Citation>Drake LY, Kita H (2017) IL-33: biological properties, functions, and roles in airway disease. Immunol Rev 278:173&#x2013;184. https://doi.org/10.1111/imr.12552</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12552</ArticleId><ArticleId IdType="pubmed">28658560</ArticleId><ArticleId IdType="pmc">5492954</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto SM, Subbannayya Y, Rex D et al (2018) A network map of IL-33 signaling pathway. J Cell Commun Signal 12:615&#x2013;624. https://doi.org/10.1007/s12079-018-0464-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12079-018-0464-4</ArticleId><ArticleId IdType="pubmed">29705949</ArticleId><ArticleId IdType="pmc">6039344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho KA, Suh JW, Sohn JH et al (2012) IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol 302:L429&#x2013;L440. https://doi.org/10.1152/ajplung.00252.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00252.2011</ArticleId><ArticleId IdType="pubmed">22180658</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DE (2010) IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 40:200&#x2013;208. https://doi.org/10.1111/j.1365-2222.2009.03384.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.2009.03384.x</ArticleId><ArticleId IdType="pubmed">19906013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani F, Babaie F, Aslani S et al (2022) The role of the IL-33/ST2 immune pathway in autoimmunity: new insights and perspectives. Immunol Invest.&#xa0;51(4):1060&#x2013;1086.&#xa0;&#xa0; https://doi.org/10.1080/08820139.2021.1878212</Citation></Reference><Reference><Citation>Italiani P, Manca ML, Angelotti F et al (2018) IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 20:27. https://doi.org/10.1186/s13075-018-1525-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1525-z</ArticleId><ArticleId IdType="pubmed">29422069</ArticleId><ArticleId IdType="pmc">5806463</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Zhou M, Zhao S et al (2019) Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus. Clin Immunol 202:49&#x2013;58. https://doi.org/10.1016/j.clim.2019.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.03.008</ArticleId><ArticleId IdType="pubmed">30926441</ArticleId><ArticleId IdType="pmc">8191378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok MY, Huang FP, Ip WK et al (2010) Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49:520&#x2013;527. https://doi.org/10.1093/rheumatology/kep402</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep402</ArticleId><ArticleId IdType="pubmed">20026564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Xie L, Qin H et al (2019) Interaction between IL-33 Gene Polymorphisms and Current Smoking with Susceptibility to Systemic Lupus Erythematosus. J Immunol Res 2019:1547578. https://doi.org/10.1155/2019/1547578</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1547578</ArticleId><ArticleId IdType="pubmed">30984790</ArticleId><ArticleId IdType="pmc">6432724</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Xiang Y, Peng YF et al (2016) The association of novel IL-33 polymorphisms with sIL-33 and risk of systemic lupus erythematosus. Mol Immunol 77:1&#x2013;7. https://doi.org/10.1016/j.molimm.2016.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.07.001</ArticleId><ArticleId IdType="pubmed">27449905</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu Y, Ye D (2016) Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population. Immunol Invest 45:575&#x2013;583. https://doi.org/10.1080/08820139.2016.1193868</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2016.1193868</ArticleId><ArticleId IdType="pubmed">27603301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe BA, Crabtree JS, Khan AS (1996) DNA isolation and sequencing. Wiley</Citation></Reference><Reference><Citation>Untergasser A, Nijveen H, Rao X et al (2007) Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35:W71&#x2013;W74. https://doi.org/10.1093/nar/gkm306</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm306</ArticleId><ArticleId IdType="pubmed">17485472</ArticleId><ArticleId IdType="pmc">1933133</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat protoc 3:1101&#x2013;1108. https://doi.org/10.1038/nprot.2008.73</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong Y, Lin H (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97&#x2013;98. https://doi.org/10.1038/sj.cr.7290272</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Liang Y, Xi W et al (2011) Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 11:75&#x2013;80. https://doi.org/10.1007/s10238-010-0115-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-010-0115-4</ArticleId><ArticleId IdType="pubmed">20963466</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugos B, Vincze Z, Sipka S et al (2012) Serum and urinary cytokine levels of SLE patients. Pharmazie 67:411&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pubmed">22764573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok MY, Huang FP, Ip WK et al (2010) Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 49:520&#x2013;527. https://doi.org/10.1093/rheumatology/kep402</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep402</ArticleId><ArticleId IdType="pubmed">20026564</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Lin W, Zheng X (2014) IL-33 neutralization suppresses lupus disease in lupus-prone mice. Inflammation 37:824&#x2013;832. https://doi.org/10.1007/s10753-013-9802-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-013-9802-0</ArticleId><ArticleId IdType="pubmed">24398614</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro JR, Fuzii HT, Kayser C et al (2011) IL-2, IL-5, TNF-&#x3b1; and IFN-&#x3b3; mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics 66:77&#x2013;82. https://doi.org/10.1590/s1807-59322011000100014</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1807-59322011000100014</ArticleId><ArticleId IdType="pubmed">21437440</ArticleId><ArticleId IdType="pmc">3044589</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Mej&#xed;as R, Genre F, Remuzgo-Mart&#xed;nez S et al (2015) Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients. PLoS One 10:e0143153. https://doi.org/10.1371/journal.pone.0143153</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143153</ArticleId><ArticleId IdType="pubmed">26571131</ArticleId><ArticleId IdType="pmc">4646618</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Mu R, Guo J et al (2014) Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther 16:1&#x2013;10. https://doi.org/10.1186/ar4554</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4554</ArticleId></ArticleIdList></Reference><Reference><Citation>Koca SS, Pehlivan Y, Kara M et al (2016) The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int 36:579&#x2013;584. https://doi.org/10.1007/s00296-015-3417-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-015-3417-8</ArticleId><ArticleId IdType="pubmed">26743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Koca SS, Kara M, Deniz F et al (2015) Serum IL-33 level and IL-33 gene polymorphisms in Beh&#xe7;et&#x2019;s disease. Rheumatol Int 35:471&#x2013;477. https://doi.org/10.1007/s00296-014-3111-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3111-2</ArticleId><ArticleId IdType="pubmed">25119832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu Y, Ye D (2016) Association between IL-33 gene polymorphisms (rs1929992, rs7044343) and systemic lupus erythematosus in a Chinese Han population. Immunol Invest 45:575&#x2013;583. https://doi.org/10.1080/08820139.2016.1193868</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2016.1193868</ArticleId><ArticleId IdType="pubmed">27603301</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan D, Ding N, Yang T et al (2014) Single nucleotide polymorphisms of the interleukin-33 (IL-33) gene are associated with ankylosing spondylitis in Chinese individuals: a case-control pilot study. Scand J Rheumatol 43:374&#x2013;379. https://doi.org/10.3109/03009742.2014.882408</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2014.882408</ArticleId><ArticleId IdType="pubmed">24825247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Xie L, Qin H et al (2019) Interaction between IL-33 gene polymorphisms and current smoking with susceptibility to systemic lupus erythematosus. J Immunol Res 2019:1547578. https://doi.org/10.1155/2019/1547578</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1547578</ArticleId><ArticleId IdType="pubmed">30984790</ArticleId><ArticleId IdType="pmc">6432724</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>